Stifel sees path towards differentiation for Viridian after Amgen data

1 hour ago 2

TipRanks

Tue, April 7, 2026 astatine 9:45 AM CDT 1 min read

Stifel expert Alex Thompson notes that Amgen (AMGN) announced affirmative topline results for the Phase 3 on-body infusion survey of Tepezza achieving a 77% complaint of proptosis response, which comes successful higher connected some an implicit and placebo-adjusted ground compared to Viridian Therapeutics’ (VRDN) elegrobar. However, with elegrobart’s subcutaneous injection illustration versus on-body infusion, the steadfast sees a way towards differentiation successful the market, says the analyst, who has a Buy standing connected Viridian shares.

  • Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

  • Discover top-performing banal ideas and upgrade to a portfolio of marketplace leaders with Smart Investor Picks

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected VRDN:

Disclaimer & DisclosureReport an Issue

  • Evercore cuts Viridian terms target, removes from ‘Tactical Outperform’ list

  • Viridian Therapeutics terms people lowered to $37 from $44 astatine Wedbush

  • Viridian Therapeutics terms people lowered to $20 from $29 astatine Wells Fargo

  • Viridian Therapeutics terms people lowered to $36 from $41 astatine Goldman Sachs

  • Viridian Therapeutics terms people lowered to $22 from $34 astatine H.C. Wainwright

Read Entire Article